Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bernhard R Winkelmann

Showing results (31-40 of 79) with videos related to

Pageof 8
Sort By:
Journal of Hypertension|December 23, 2004
Association analysis of the polymorphism T1128C in the signal peptide of neuropeptide Y in a Swedish hypertensive populationWilfried Renner, Tanja Grammer, Michael M Hoffmann, et al.
Atherosclerosis|February 7, 2012
Duration of type 2 diabetes strongly predicts all-cause and cardiovascular mortality in people referred for coronary angiographyGuenther Silbernagel, Silke Rosinger, Tanja B Grammer, et al.
European Heart Journal|August 11, 2004
Association of RANTES G-403A gene polymorphism with increased risk of coronary arteriosclerosisEleonora Simeoni, Bernhard R Winkelmann, Michael M Hoffmann, et al.
BMC Medical Genetics|April 25, 2009
Genetic variants of the promoter of the heme oxygenase-1 gene and their influence on cardiovascular disease (the Ludwigshafen Risk and Cardiovascular Health study)Nicola Lüblinghoff, Karl Winkler, Bernhard R Winkelmann, et al.
Clinical Chemistry|July 31, 2008
Apolipoprotein A-II Is a negative risk indicator for cardiovascular and total mortality: findings from the Ludwigshafen Risk and Cardiovascular Health StudyKarl Winkler, Michael M Hoffmann, Ursula Seelhorst, et al.
Clinical Endocrinology|January 3, 2008
Effect of the resistin -420C > G polymorphism on cardiovascular disease and mortalityMichael M Hoffmann, Stefan Pilz, Gisela Weihrauch, et al.
Atherosclerosis|February 12, 2011
Apolipoprotein E genotypes, circulating C-reactive protein and angiographic coronary artery disease: the Ludwigshafen Risk and Cardiovascular Health StudyTanja B Grammer, Michael M Hoffmann, Wilfried Renner, et al.
Journal of Molecular Medicine (Berlin, Germany)|December 16, 2004
Association of angiotensinogen haplotypes with angiotensinogen levels but not with blood pressure or coronary artery disease: the Ludwigshafen Risk and Cardiovascular Health StudyWilfried Renner, Markus Nauck, Bernhard R Winkelmann, et al.
Circulation|June 3, 2004
G(-30)A polymorphism in the pancreatic promoter of the glucokinase gene associated with angiographic coronary artery disease and type 2 diabetes mellitusWinfried März, Markus Nauck, Michael M Hoffmann, et al.
Clinical Chemistry|November 2, 2010
Symmetrical and asymmetrical dimethylarginine as predictors for mortality in patients referred for coronary angiography: the Ludwigshafen Risk and Cardiovascular Health studyAndreas Meinitzer, Jan T Kielstein, Stefan Pilz, et al.
Pageof 8

Showing results (31-40 of 79) with videos related to

Sort By:
Pageof 8
Journal of Hypertension|December 23, 2004
Association analysis of the polymorphism T1128C in the signal peptide of neuropeptide Y in a Swedish hypertensive populationWilfried Renner, Tanja Grammer, Michael M Hoffmann, et al.
Atherosclerosis|February 7, 2012
Duration of type 2 diabetes strongly predicts all-cause and cardiovascular mortality in people referred for coronary angiographyGuenther Silbernagel, Silke Rosinger, Tanja B Grammer, et al.
European Heart Journal|August 11, 2004
Association of RANTES G-403A gene polymorphism with increased risk of coronary arteriosclerosisEleonora Simeoni, Bernhard R Winkelmann, Michael M Hoffmann, et al.
BMC Medical Genetics|April 25, 2009
Genetic variants of the promoter of the heme oxygenase-1 gene and their influence on cardiovascular disease (the Ludwigshafen Risk and Cardiovascular Health study)Nicola Lüblinghoff, Karl Winkler, Bernhard R Winkelmann, et al.
Clinical Chemistry|July 31, 2008
Apolipoprotein A-II Is a negative risk indicator for cardiovascular and total mortality: findings from the Ludwigshafen Risk and Cardiovascular Health StudyKarl Winkler, Michael M Hoffmann, Ursula Seelhorst, et al.
Clinical Endocrinology|January 3, 2008
Effect of the resistin -420C > G polymorphism on cardiovascular disease and mortalityMichael M Hoffmann, Stefan Pilz, Gisela Weihrauch, et al.
Atherosclerosis|February 12, 2011
Apolipoprotein E genotypes, circulating C-reactive protein and angiographic coronary artery disease: the Ludwigshafen Risk and Cardiovascular Health StudyTanja B Grammer, Michael M Hoffmann, Wilfried Renner, et al.
Journal of Molecular Medicine (Berlin, Germany)|December 16, 2004
Association of angiotensinogen haplotypes with angiotensinogen levels but not with blood pressure or coronary artery disease: the Ludwigshafen Risk and Cardiovascular Health StudyWilfried Renner, Markus Nauck, Bernhard R Winkelmann, et al.
Circulation|June 3, 2004
G(-30)A polymorphism in the pancreatic promoter of the glucokinase gene associated with angiographic coronary artery disease and type 2 diabetes mellitusWinfried März, Markus Nauck, Michael M Hoffmann, et al.
Clinical Chemistry|November 2, 2010
Symmetrical and asymmetrical dimethylarginine as predictors for mortality in patients referred for coronary angiography: the Ludwigshafen Risk and Cardiovascular Health studyAndreas Meinitzer, Jan T Kielstein, Stefan Pilz, et al.
Pageof 8